ThisCART19A

also known as FT400-011 · ThisCART19

Developed for: B-cell non-Hodgkin lymphoma · T-cell Subgroups, non-HLA-linked · adult acute lymphoblastic leukemia · autoimmune hemolytic anemia · B-cell neoplasm · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · HIV-associated cancer · non-Hodgkin lymphoma
Investigated by: Fundamenta Therapeutics, Ltd. · The First Affiliated Hospital of Soochow University · Zhejiang University · Chongqing University Cancer Hospital · He Huang · Henan Cancer Hospital
+4 more
· Institute of Hematology & Blood Diseases Hospital, China · Suzhou Fundamenta Therapeutics · The First Affiliated Hospital of Zhengzhou University · Zhengzhou University

Trials 12 · a red edge is where a trial was stopped

today NCT06212154 · Ph 1 NCT07074496 · Ph 0 NCT05776407 · Ph 1/2 NCT05691153 · Ph 1 NCT05640713 · Ph 1 NCT05679687 · Ph 1 NCT05576181 · Ph 1 NCT05535673 · Ph 1 NCT05349266 · Ph 1 NCT05340829 · Ph 1 NCT05350852 · Ph 1 NCT05350787 · Ph 1

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07074496	Jan 2024 → Nov 2025 overdue	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	The First Affiliated Hospital of Soochow University	Recruiting	No outcome recorded
Phase 110 trials
Phase 1	NCT06212154	Jan → Dec 2024	B-lymphoblastic leukemia/lymphoma with t(17;19), autoimmune hemolytic anemia	Institute of Hematology & Blood Diseases Hospital, China	Unknown	No outcome recorded
Phase 1	NCT05691153	Dec 2022 → Nov 2025	B-cell neoplasm, non-Hodgkin lymphoma	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 1	NCT05640713	Dec 2022 → Feb 2025	T-cell Subgroups, non-HLA-linked	Henan Cancer Hospital	Unknown	No outcome recorded
Phase 1	NCT05679687	Dec 2022 → Nov 2025	adult acute lymphoblastic leukemia	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 1	NCT05576181	Oct 2022 → Jan 2025	T-cell Subgroups, non-HLA-linked	Fundamenta Therapeutics, Ltd.	Unknown	No outcome recorded
Phase 1	NCT05535673	Sep 2022 → Jul 2025	—	Zhengzhou University	Unknown	No outcome recorded
Phase 1	NCT05349266	Mar 2022 → Mar 2024	B-cell non-Hodgkin lymphoma	Zhejiang University	Unknown	No outcome recorded
Phase 1	NCT05340829	Mar 2022 → Mar 2024	HIV-associated cancer	He Huang	Unknown	No outcome recorded
Phase 1	NCT05350852	Mar 2022 → Mar 2024	—	Zhejiang University	Unknown	No outcome recorded
Phase 1	NCT05350787	Mar 2022 → May 2025	—	Zhejiang University	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT05776407	May 2023 → May 2024	B-cell non-Hodgkin lymphoma	Chongqing University Cancer Hospital	Unknown	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

Field	Value	Cited text
Known as	ThisCART19A	“allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed...” NCT05679687 ↗ 11 NCT05349266 ↗ NCT05350787 ↗ NCT05350852 ↗ NCT05535673 ↗ NCT05576181 ↗ NCT05776407 ↗ NCT05691153 ↗ NCT05640713 ↗ NCT06212154 ↗ NCT05340829 ↗ NCT07074496 ↗
Known as	FT400-011	“ThisCART19A （FT400-011）” NCT05640713 ↗
Known as	ThisCART19	“This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) Bridging Hematopoietic Stem Cell Transplantation” NCT05576181 ↗
Modality	Cell therapy	“ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia” NCT05340829 ↗
Route	Other	“allogeneic anti-CD19 CAR T cell (ThisCART19A) infusion” NCT05640713 ↗
Target	CD19	“CAR-T targeting CD19” NCT05535673 ↗